Skip to content

Prospective Multicenter Clinical Study and Mechanistic Investigation of Yangluanfang for the Treatment of Diminished Ovarian Reserve

Prospective Multicenter Clinical Study and Mechanistic Investigation of Yangluanfang for the Treatment of Diminished Ovarian Reserve

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001039
Enrollment
Unknown
Registered
2026-04-22
Start date
2025-01-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished Ovarian Reserve

Interventions

Decreased Ovarian Reserve group:Give Chinese medicine

Sponsors

Zhejiang Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria of the expert consensus on the clinical diagnosis and treatment of ovarian reserve (2022 version); (2) Females of childbearing age 21~45 years old; (3) The patient voluntarily underwent clinical observation and signed the informed consent form. The diagnostic criteria in this study were formulated with reference to the Obstetrics and Gynecology (9th Edition) and the Expert Consensus on the Clinical Diagnosis and Treatment of Hypoactive Ovarian Reserve (2022 Edition): (1) AMH 10 IU/L for 2 consecutive menstrual cycles of which (1)~(3) can be diagnosed if any one of them is satisfied.

Exclusion criteria

Exclusion criteria: (1) Those who do not meet the diagnostic criteria for inclusion; (2) Combined with serious internal diseases such as heart brain lung diseases or combined with psychiatric diseases and communication disorders; (3) Tumors of the reproductive system and congenital malformations of reproductive organs; (4) genetic factors; (5) Received other exogenous hormones Chinese medicines or proprietary Chinese medicines within 3 months.

Design outcomes

Primary

MeasureTime frame
From the first medication to after 2 menstrual cycles, changes from baseline in serum AMH levels;Pregnancy rate after the first use of medication for 2 menstrual cycles;From the first medication to after 2 menstrual cycles, IVF outcomes (number of oocytes retrieved, fertilization rate, usable embryo rate);Chinese medicine syndrome score from the first medication to after 2 menstrual cycles;

Secondary

MeasureTime frame
Bilateral ovarian AFC after the first medication up to 2 menstrual cycles;From the first dose to after 2 menstrual cycles, serum baseline hormone levels (FSH, LH, E2, etc.);

Countries

China

Contacts

Public ContactZhou Feifei

Zhejiang Provincial People's Hospital

5510025@zju.edu.cn13968153377

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026